GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hindustan Bio Sciences Ltd (BOM:532041) » Definitions » Return-on-Tangible-Equity

Hindustan Bio Sciences (BOM:532041) Return-on-Tangible-Equity : 40.02% (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Hindustan Bio Sciences Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hindustan Bio Sciences's annualized net income for the quarter that ended in Dec. 2023 was ₹2.76 Mil. Hindustan Bio Sciences's average shareholder tangible equity for the quarter that ended in Dec. 2023 was ₹6.91 Mil. Therefore, Hindustan Bio Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 40.02%.

The historical rank and industry rank for Hindustan Bio Sciences's Return-on-Tangible-Equity or its related term are showing as below:

BOM:532041' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -71.3   Med: -15.06   Max: 20.8
Current: 20.8

During the past 13 years, Hindustan Bio Sciences's highest Return-on-Tangible-Equity was 20.80%. The lowest was -71.30%. And the median was -15.06%.

BOM:532041's Return-on-Tangible-Equity is ranked better than
82.84% of 938 companies
in the Drug Manufacturers industry
Industry Median: 6.3 vs BOM:532041: 20.80

Hindustan Bio Sciences Return-on-Tangible-Equity Historical Data

The historical data trend for Hindustan Bio Sciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hindustan Bio Sciences Return-on-Tangible-Equity Chart

Hindustan Bio Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.22 3.67 -52.96 -49.48 -5.28

Hindustan Bio Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.61 27.71 6.38 36.91 40.02

Competitive Comparison of Hindustan Bio Sciences's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Hindustan Bio Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hindustan Bio Sciences's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hindustan Bio Sciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Hindustan Bio Sciences's Return-on-Tangible-Equity falls into.



Hindustan Bio Sciences Return-on-Tangible-Equity Calculation

Hindustan Bio Sciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-0.405/( (7.871+7.466 )/ 2 )
=-0.405/7.6685
=-5.28 %

Hindustan Bio Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=2.764/( (6.906+0)/ 1 )
=2.764/6.906
=40.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Hindustan Bio Sciences  (BOM:532041) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Hindustan Bio Sciences Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Hindustan Bio Sciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Hindustan Bio Sciences (BOM:532041) Business Description

Traded in Other Exchanges
N/A
Address
Road No. 2, Banjara Hills, H.No. 8-2-269/S, Plot No. 31, Sagar Co-Operative Housing Society, Hyderabad, TG, IND, 500034
Hindustan Bio Sciences Ltd is an India-based company operating in the pharmaceutical and biotechnology sector. It is engaged in the trading of Drugs and Medicines. The company markets a nephrology product, Recombinant Human Erythropoietin, which is useful for the treatment of anemia associated with chronic renal failure. In addition, the firm also manufactures and markets pharmaceutical products in different forms such as tablets, capsules, drops, externals, and syrups. Its other formulations comprise Pantorest, Maxion, Edinil, Aromycin, Livohin and others. Geographically, the group sells its products within India and also exports it to other countries.

Hindustan Bio Sciences (BOM:532041) Headlines

No Headlines